Katherine Weilbaecher

Oncology
4921 Parkview Pl
Saint Louis, MO 63110

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 78 publications

CDK4/6 inhibitor ribociclib and doxorubicin combination treatment inhibits breast cancer bone metastasis and enhances T-cell targeted therapy.

CDK4/6 inhibitor ribociclib and doxorubicin combination treatment inhibits breast cancer bone metastasis and enhances T-cell targeted therapy.

Journal: Journal of bone oncology
Published: January 07, 2026

Remission of longstanding metastatic paraganglioma in a patient after use of zoledronic acid.

Remission of longstanding metastatic paraganglioma in a patient after use of zoledronic acid.

Journal: BMJ case reports
Published: November 29, 2024

Detection of Circulating Tumor DNA Using a Tissue-Free Epigenomic Assay Is a Highly Prognostic Biomarker in Early-Stage Triple-Negative Breast Cancer.

Detection of Circulating Tumor DNA Using a Tissue-Free Epigenomic Assay Is a Highly Prognostic Biomarker in Early-Stage Triple-Negative Breast Cancer.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: October 21, 2024

The New Proposed U.S. Preventive Services Task Force Recommendation on Breast Cancer Screening for Women in Their 40s.

The New Proposed U.S. Preventive Services Task Force Recommendation on Breast Cancer Screening for Women in Their 40s.

Journal: Annals of internal medicine
Published: September 16, 2024

Chemotherapy and the Extra-Tumor Immune Microenvironment: EXTRA-TIME.

Chemotherapy and the Extra-Tumor Immune Microenvironment: EXTRA-TIME.

Journal: Cancer discovery
Published: April 04, 2024

Induction of complementary immunogenic necroptosis and apoptosis cell death pathways inhibits cancer metastasis and relapse.

Induction of complementary immunogenic necroptosis and apoptosis cell death pathways inhibits cancer metastasis and relapse.

Journal: Research square
Published: April 01, 2024

HTLV-1 infected T cells cause bone loss via small extracellular vesicles.

HTLV-1 infected T cells cause bone loss via small extracellular vesicles.

Journal: bioRxiv : the preprint server for biology
Published: March 18, 2024

Radionuclide-stimulated dynamic therapy induces complementary immunogenic necroptosis and apoptosis cancer cell death pathways.

Radionuclide-stimulated dynamic therapy induces complementary immunogenic necroptosis and apoptosis cancer cell death pathways.

Journal: Communications biology
Published: February 28, 2024

HTLV-1 infected T cells cause bone loss via small extracellular vesicles.

HTLV-1 infected T cells cause bone loss via small extracellular vesicles.

Journal: Journal of extracellular vesicles
Published: January 19, 2024

BCAR4 Expression as a Predictive Biomarker for Endocrine Therapy Resistance in Breast Cancer.

BCAR4 Expression as a Predictive Biomarker for Endocrine Therapy Resistance in Breast Cancer.

Journal: Clinical breast cancer
Published: November 09, 2023

Resistance to abemaciclib is associated with increased metastatic potential and lysosomal protein deregulation in breast cancer cells.

Resistance to abemaciclib is associated with increased metastatic potential and lysosomal protein deregulation in breast cancer cells.

Journal: Molecular carcinogenesis
Published: August 11, 2023

Transferrin receptor in primary and metastatic breast cancer: Evaluation of expression and experimental modulation to improve molecular targeting.

Transferrin receptor in primary and metastatic breast cancer: Evaluation of expression and experimental modulation to improve molecular targeting.

Journal: PloS one
Published: August 09, 2023
Showing 1-12 of 78

Last Updated: 09/26/2026